Metabolism of CPT-11: Impact on activity

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 205-215

  Rivory, Laurent P ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CYTOCHROME P450 3A; IRINOTECAN; PRODRUG;

ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; DRUG ACTIVATION; DRUG CONJUGATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; ENTEROHEPATIC CIRCULATION; HUMAN; INTESTINE; LIVER METABOLISM; NONHUMAN;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0034502464     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07039.x     Document Type: Conference Paper

References (63)

1. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin
2. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse
3. Nonlinear pharmacokinetics of CPT-11 in rats
4. 14C]CPT-11 in patients with advanced solid tumor malignancy
5. Irinotecan (CPT-11) metabolism and disposition in cancer patients
6. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer
7. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials
8. Clinical pharmacokinetics of irinotecan
9. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials
10. CPT-11 converting enzyme from rat serum: Purification and some properties
11. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase
12. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
13. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues
14. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase
15. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms
16. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients
17. Phase I and pharmacokinetic study of irintotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors
18. Phase I clinical and pharmacokinetic study of 5 day CPT-11 hepatic arterial infusion (HAI) chemotherapy
19. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability
20. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions
21. Phase I and pharmacokinetic trial of weekly CPT-11
22. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
23. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients
24. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children
25. Pharmacokinetics of irinotecan (CPT-11) and its metabolites in children
26. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)
27. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase
28. Determinants of CPT-11 and SN-38 activities in human lung cancer cells
29. CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants
30. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA
31. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors
32. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy
33. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase
34. In vitro activation of irinotecan to SN-38 by human liver and intestine
35. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
36. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts
37. A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11
38. Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance
39. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
40. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
41. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions
42. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes
43. Irinotecan (CPT-11) metabolites in human bile and urine
44. The detection of photodegradation products of irinotecan (CPT-11, Campto, Camptosar), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry
45. Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver
46. Further elucidation of the pathways involved in the catabolism of the camptothecin analogue irinotecan
47. CYP3A4 and CYP3A5 metabolism of irinotecan (CPT-11) in humans
48. Photodegradation of irinotecan (CPT-11) in aqueous solutions: Identification of fluorescent products and influence of solution composition
49. Pharmacokinetics of irinotecan (CPT-11) in recurrent glioma patients: Results of an NCCTG phase II trial
50. Irinotecan therapy in adults with recurrent or progressive malignant glioma
51. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
52. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan
53. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
54. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
55. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
56. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
57. Bilirubin (Bil) and SN-38 metabolism: Pharmacodynamics of CPT-11
58. Phase I and pharmacokinetic (PK) study of irinotecan (CPT-11) in cancer patients (pts) with hepatic dysfunction
59. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
60. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats
61. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate
62. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
63. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin (SN-38) resistance